0.18
-0.005(-2.70%)
Currency In CAD
Address
The Stiller Centre
London, ON N6G 4X8
United Kingdom of Great Britain and Northern Ireland
Phone
519 858 5184
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
April 29, 1999
| Name | Title | Pay | Year Born |
| Mr. Jonathan M. N. Rigby M.B.A., MBA | Chief Executive Officer & Director | 693,397 | 1968 |
| Dr. Frank Shannon M.D. | Senior Vice President of Clinical Development and Regulatory Affairs | 335,833 | N/A |
| Mr. James T. Parsons CPA-CA, MAcc | Chief Financial Officer | 467,182 | 1965 |
| Dr. Modestus Obochi M.B.A., Ph.D. | Chief Business Officer | 499,487 | N/A |
| Dr. Pericles Calias Ph.D. | Chief Development Officer and Head of R&D | 0 | 1968 |
| Ms. Marylyn Rigby | Chief Communications Officer | 0 | N/A |
| Mr. David Burke | Vice President of Investor Relations | 0 | N/A |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.